Alto Neuroscience, Inc.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company dedicated to redefining psychiatry through a precision medicine approach. The company's mission is to leverage neurobiology to develop personalized and highly effective treatment options for neuropsychiatric disorders. Founded in 2019 by Dr. Amit Etkin, Alto Neuroscience is headquartered in Mountain View, California.

Alto Neuroscience's core business revolves around its proprietary Precision Psychiatry Platform™, which measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors. This platform aims to identify which patients are most likely to respond to specific drug candidates, thereby moving beyond traditional trial-and-error treatment methods. The company's clinical-stage pipeline includes several drug candidates, such as ALTO-100, ALTO-300, ALTO-207, ALTO-101, ALTO-202, ALTO-203, and ALTO-208, targeting conditions like major depressive disorder (MDD), bipolar depression, treatment-resistant depression (TRD), and schizophrenia.

Recent developments include the initiation of a Phase 2b clinical trial for ALTO-207 in treatment-resistant depression during the first quarter of 2026. The company also successfully closed a $120 million private placement financing (PIPE) in March 2026, which is expected to fund operations through 2029. While a Phase 2 proof-of-concept study for ALTO-101 did not meet its primary statistical significance endpoints, it showed directional improvements. Dr. Amit Etkin, the company's founder, serves as President, CEO, and Chairman of the Board.